Bank of New York Mellon Corp boosted its holdings in shares of VIVUS, Inc. (NASDAQ:VVUS) by 7.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 114,564 shares of the biopharmaceutical company’s stock after buying an additional 7,722 shares during the period. Bank of New York Mellon Corp owned approximately 0.11% of VIVUS worth $140,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Spark Investment Management LLC acquired a new position in VIVUS during the second quarter valued at $100,000. Russell Investments Group Ltd. raised its position in VIVUS by 84.8% during the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 68,200 shares during the period. Acadian Asset Management LLC raised its position in VIVUS by 70.9% during the second quarter. Acadian Asset Management LLC now owns 1,837,822 shares of the biopharmaceutical company’s stock valued at $2,241,000 after buying an additional 762,392 shares during the period. Finally, Renaissance Technologies LLC raised its position in VIVUS by 41.2% during the first quarter. Renaissance Technologies LLC now owns 6,182,454 shares of the biopharmaceutical company’s stock valued at $6,924,000 after buying an additional 1,805,100 shares during the period. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on the company. Zacks Investment Research raised VIVUS from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Monday, July 17th. ValuEngine raised VIVUS from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd.

VIVUS, Inc. (NASDAQ VVUS) opened at $0.68 on Tuesday. The company has a debt-to-equity ratio of 40.25, a current ratio of 5.51 and a quick ratio of 5.20. VIVUS, Inc. has a 52-week low of $0.61 and a 52-week high of $1.47. The firm has a market capitalization of $72.16, a PE ratio of 2.20 and a beta of 0.82.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/vivus-inc-vvus-position-lifted-by-bank-of-new-york-mellon-corp/1684389.html.

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Want to see what other hedge funds are holding VVUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VIVUS, Inc. (NASDAQ:VVUS).

Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.